Related Experiment Videos
Physostigmine reversal of scopolamine-induced hypofrontality
I Prohovnik1, S E Arnold, G Smith
1Department of Brain Imaging, New York State Psychiatric Institute, College of Physicians and Surgeons, Columbia University, New York, USA.
Summary
Scopolamine causes memory loss and reduced frontal brain blood flow in healthy individuals. These effects are centrally mediated and reversed by physostigmine, but differ from Alzheimer's disease patterns.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Scopolamine, a muscarinic antagonist, induces memory deficits, modeled as a cholinergic deficit in Alzheimer's disease (AD).
- Previous studies show scopolamine reduces frontal cortical perfusion, unlike the parietal deficit typical of AD.
Purpose of the Study:
- To replicate and extend findings on scopolamine's effects on cognition and cerebral blood flow.
- To critically test the central cholinergic origin of scopolamine-induced deficits and their reversal.
Main Methods:
- Regional cerebral blood flow (rCBF) was measured in nine healthy subjects using xenon 133 inhalation.
- Measurements were taken at baseline, after scopolamine administration, and after physostigmine or neostigmine administration.
Main Results:
- Scopolamine reduced cortical perfusion (mainly frontal) and impaired memory.
- Physostigmine, but not neostigmine, partially or fully reversed these effects.
- Findings support a central cholinergic mediation of scopolamine's effects.
Conclusions:
- Scopolamine's cognitive and perfusion deficits are centrally mediated via cholinergic pathways.
- The frontal cortex is the primary site of action for scopolamine and its reversal.
- These centrally mediated frontal effects differ significantly from the parietal deficits observed in Alzheimer's disease.